2015 Annual Report

Dear Members Of The Acorda Community:

We aim to grow Acorda into the preeminent biopharmaceutical company delivering innovative therapies for people with neurological disorders, and are building on three pillars to drive long-term value creation:

  • Advancing our diversified clinical pipeline to approval and commercialization;
  • Acquiring assets that leverage our core competencies in neurology; and
  • Continuing to grow sales in multiple sclerosis of AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.